Syndax Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Syndax Pharmaceuticals, Inc. (SNDX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$49.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$49.36M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$42.67M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$68.01M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$60.72M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$285.42M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$318.76M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$209.36M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$149.34M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.36M 10-Q · filed 2026-08-04 | -$92.04M 10-Q · filed 2026-08-04 | -$160.05M derived: sum of 3 quarters · filed 2026-08-04 | -$220.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$42.67M 10-Q · filed 2026-04-30 | -$110.69M derived: sum of 2 quarters · filed 2026-04-30 | -$171.40M derived: sum of 3 quarters · filed 2026-04-30 | -$243.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$68.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$128.73M derived: sum of 2 quarters · filed 2026-02-26 | -$200.58M derived: sum of 3 quarters · filed 2026-08-04 | -$285.42M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$60.72M 10-Q · filed 2025-11-03 | -$132.56M derived: sum of 2 quarters · filed 2026-08-04 | -$217.41M 10-Q · filed 2025-11-03 | -$311.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$71.85M 10-Q · filed 2026-08-04 | -$156.69M 10-Q · filed 2026-08-04 | -$250.86M derived: sum of 3 quarters · filed 2026-08-04 | -$334.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$84.85M 10-Q · filed 2026-04-30 | -$179.01M derived: sum of 2 quarters · filed 2026-04-30 | -$263.14M derived: sum of 3 quarters · filed 2026-04-30 | -$331.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$94.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$178.29M derived: sum of 2 quarters · filed 2026-02-26 | -$246.36M derived: sum of 3 quarters · filed 2026-02-26 | -$318.76M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$84.13M 10-Q · filed 2025-11-03 | -$152.19M derived: sum of 2 quarters · filed 2025-11-03 | -$224.59M 10-Q · filed 2025-11-03 | -$297.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$68.06M 10-Q · filed 2025-08-04 | -$140.46M 10-Q · filed 2025-08-04 | -$212.94M derived: sum of 3 quarters · filed 2026-02-26 | -$264.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$72.40M 10-Q · filed 2025-05-05 | -$144.87M derived: sum of 2 quarters · filed 2026-02-26 | -$196.02M derived: sum of 3 quarters · filed 2026-02-26 | -$240.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$72.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$123.62M derived: sum of 2 quarters · filed 2026-02-26 | -$168.23M derived: sum of 3 quarters · filed 2026-02-26 | -$209.36M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$51.15M 10-Q · filed 2024-11-05 | -$95.76M derived: sum of 2 quarters · filed 2024-11-05 | -$136.89M 10-Q · filed 2024-11-05 | -$176.08M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$44.62M 10-Q · filed 2024-08-01 | -$85.74M 10-Q · filed 2024-08-01 | -$124.94M derived: sum of 3 quarters · filed 2025-03-03 | -$160.34M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$41.13M 10-Q · filed 2024-05-08 | -$80.32M derived: sum of 2 quarters · filed 2025-03-03 | -$115.72M derived: sum of 3 quarters · filed 2025-03-03 | -$153.29M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$39.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$74.60M derived: sum of 2 quarters · filed 2025-03-03 | -$112.17M derived: sum of 3 quarters · filed 2025-03-03 | -$149.34M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$35.40M 10-Q · filed 2023-11-02 | -$72.97M derived: sum of 2 quarters · filed 2023-11-02 | -$110.14M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$37.57M 10-Q · filed 2023-08-03 | -$74.74M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$37.17M 10-Q · filed 2023-05-08 | |||
| 2021-09-30 | -$20.64M 10-Q · filed 2022-11-03 | -$43.55M derived: sum of 2 quarters · filed 2022-11-03 | -$71.27M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$22.91M 10-Q · filed 2022-08-08 | -$50.63M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |